18F-Radiolabeling and Preliminary Evaluation of a HSP90 ligand

Eur J Pharm Sci. 2021 Feb 1:157:105647. doi: 10.1016/j.ejps.2020.105647. Epub 2020 Nov 20.

Abstract

Purpose: With the ambition of improving the management of pancreatic neuroendocrine tumors (P-NETs), we developed and preliminary validated a novel fluorine-18 labelled HSP90 ligand.

Methods: A precursor containing methoxymethyl ethers protecting groups and a tosyl as leaving group was synthesized. The target compound was labeled with nucleophilic 18F-fluoride and the protecting groups was subsequently removed with hydrochloric acid before purification. In vitro cell- and frozen section autoradiography and in vivo animal studies were performed.

Results: The precursor was successfully synthesized and utilized in the 18F-radiolabeling giving 0.5-1.0 GBq of pure product with a synthesis time of 70 min. In vitro experiments indicated a high specific binding, but in vivo studies showed no tumor uptake due to fast hepatobiliary metabolism and excretion.

Conclusions: Despite the unfavorable in vivo properties of the tracer, the promising results from in vitro autoradiography experiments in frozen sections of P-NETs from surgical resection encourage us to continue the project aiming the improvement of in vivo properties of the tracer.

Keywords: HSP(90); PET; cancer; fluorine-18.

MeSH terms

  • Animals
  • Autoradiography
  • Fluorides*
  • Fluorine Radioisotopes
  • Ligands
  • Positron-Emission Tomography*
  • Radiopharmaceuticals

Substances

  • Fluorine Radioisotopes
  • Ligands
  • Radiopharmaceuticals
  • Fluorides